{"id":619014,"date":"2026-08-04T00:17:10","date_gmt":"2026-08-04T00:17:10","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/619014\/"},"modified":"2026-08-04T00:17:10","modified_gmt":"2026-08-04T00:17:10","slug":"eli-lilly-to-offer-retatrutide-access-given-earlier-to-just-one-patient","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/619014\/","title":{"rendered":"Eli Lilly to offer retatrutide access given earlier to just one patient"},"content":{"rendered":"

Lizzy leads STAT\u2019s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency\u2019s ability to protect and promote public health. Confidential tips can be sent on Signal at lizzylaw.53.<\/p>\n

Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n

Six weeks after STAT reported that Eli Lilly granted<\/a> a single 79-year-old patient special access to retatrutide, an unapproved obesity drug, the company confirmed on Monday that it will allow other patients to apply for early access.\u00a0<\/p>\n

The announcement comes after STAT asked Lilly about the requests for expanded access from a handful of doctors who had not yet received a reply from the drugmaker. It marks a striking change in the public posture of the pharmaceutical giant, which had previously offered little information about the special access program.\u00a0<\/p>\n

\t\t\t\"\"\t\t<\/p>\n

\t\t\t\t\"\"\/
\n\t\t\t\tSTAT Plus: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?<\/a><\/p>\n

\u201cFor a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA\u2019s guidance,\u201d a Lilly spokesperson told STAT. The company said it is actively reviewing requests from health care providers.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Lizzy leads STAT\u2019s coverage of the FDA. Her stories explore the relationship between politics and science at the…\n","protected":false},"author":2,"featured_media":619015,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[274],"tags":[7593,243,18,2898,135,19,17,462,2900,12318,2850],"class_list":["post-619014","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-biotechnology","tag-drug-development","tag-eire","tag-fda","tag-health","tag-ie","tag-ireland","tag-medication","tag-pharmaceuticals","tag-policy","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/117034369485102670","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/619014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=619014"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/619014\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/619015"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=619014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=619014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=619014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}